Compare · REPL vs SGEN
REPL vs SGEN
Side-by-side comparison of Replimune Group Inc. (REPL) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both REPL and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 29.8x REPL ($782.0M).
- REPL has hit the wire 13 times in the past 4 weeks while SGEN has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Replimune Group Inc.
- Seagen Inc.
- Price
- $9.47-3.96%
- $228.86-0.01%
- Market cap
- $782.0M
- $23.34B
- 1M return
- +176.90%
- -
- 1Y return
- -6.88%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2001
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 25
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest REPL
- Chief Commercial Officer Sarchi Christopher sold $110,880 worth of shares (12,000 units at $9.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 180,962 units (SEC Form 4)
- Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- Replimune upgraded by Analyst with a new price target
- Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
- SEC Form SCHEDULE 13G filed by Replimune Group Inc.
- Chief Medical Officer Xynos Konstantinos sold $71,237 worth of shares (14,023 units at $5.08), decreasing direct ownership by 6% to 235,662 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Schwendenman Andrew sold $40,102 worth of shares (7,894 units at $5.08), decreasing direct ownership by 7% to 107,057 units (SEC Form 4) to cover taxes
- Chief Commercial Officer Sarchi Christopher sold $43,820 worth of shares (8,626 units at $5.08), decreasing direct ownership by 4% to 192,962 units (SEC Form 4) (for tax liability)
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)